Table of Contents
Conference Papers in Science
Volume 2014, Article ID 869240, 6 pages
http://dx.doi.org/10.1155/2014/869240
Conference Paper

Biocompatibility Issues of Next Generation Decellularized Bioprosthetic Devices

1Department of Experimental Biomedical Sciences, University of Padova, Viale G. Colombo 3, 35131 Padua, Italy
2Department of Cardiac, Thoracic and Vascular Sciences, University Hospital of Padua, Via Giustiniani 2, 35128 Padua, Italy
3Department of Industrial Engineering, University of Padova, Via Marzolo 9, 35131 Padua, Italy

Received 22 November 2013; Accepted 11 March 2014; Published 12 May 2014

Academic Editors: V. La Carrubba, A. Lepedda, and J. C. Rodriguez-Cabello

This Conference Paper is based on a presentation given by Michele Spina at “LIAC Meeting on Vascular Research 2013” held from 18 September 2013 to 21 September 2013 in Alghero, Italy.

Copyright © 2014 Michele Spina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

With respect to the limited lifespan of glutaraldehyde-treated bioprostheses (BHVs) to date there is almost no alternative when heart valve replacement surgery is required and most advanced current research attempts to develop tissue engineered valve scaffolds to be implanted in vivo or after in vitro preconditioning and dynamic seeding with host cells. However the clinical outcomes of grafting detergent-based cell-depleted tissue engineered xenogeneic constructs are still controversial. Insufficient quantitative evaluations performed at preclinical level about the residual content of xenogeneic epitopes, detergents, and nucleic acid materials in such scaffolds have led to disappointing and disastrous results. The risk of these dramatic accidents reoccurring remains very high unless safety and reliable control tools aimed to reach their complete removal, in order to consider tissues biocompatible and suitable for clinical practice.